Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • reut
    Member
    • Oct 2010
    • 19

    alternative splicing in RNA-Seq

    I am analyzing RNA-Seq data, and need to focus on detecting alternative splicing events.
    I need to know which alternative splicing events occurred in the data and how do they differ between samples (increased/decreased inclusion level).

    I have started using Cufflinks tools, and I know the splicing.diff file should provide me with some information, but it's on the transcript level and not exon/alt event level.

    Does anyone have any recommendations on how to approach this?

    Thanks,
    Reut
  • fongchun
    Member
    • May 2011
    • 55

    #2
    MISO might be able to help you as it can look at the individual exon level:



    I, myself, haven't tried it yet. But the paper claims it can. So that might be one option. A simpler approach might be to just use the simple splicing index metric.

    Hope that helps,

    Fong

    Comment

    • hong_sunwoo
      Member
      • Jan 2010
      • 11

      #3
      I am trying MISO and I think that the tool is very useful for detecting difference in alternative splicing.
      It uses pre-annotated AS data sets with multiple categories such as exon skip and alternative last exon. It means you can not discover 'novel' alternative splicing event which is not included in the pre-annotated AS data.
      However, for me, it supplies lots of information about AS changes in my samples.

      Comment

      • reut
        Member
        • Oct 2010
        • 19

        #4
        Thank you for your replies,
        hong_sunwoo, can you please show me/send me an example of it's output?

        Comment

        • hong_sunwoo
          Member
          • Jan 2010
          • 11

          #5
          Originally posted by reut View Post
          Thank you for your replies,
          hong_sunwoo, can you please show me/send me an example of it's output?
          Because the data will be used for publication, I can not share you the whole data generated from MISO.

          The below is one line of the running result file.

          event_name sample1_posterior_mean sample1_ci_low sample1_ci_high sample2_posterior_mean sample2_ci_low sample2_ci_high diff bayes_factor isoforms sample1_counts sample1_assigned_counts sample2_counts sample2_assigned_counts
          blank 0.47 0.24 0.76 0.51 0.18 0.75 -0.04 0.75 blank (1,1):63 0:45,1:18 (1,1):36 0:15,1:21

          You may check the document for MISO for getting the meaning of this output.

          Comment

          • malachig
            Senior Member
            • Aug 2010
            • 117

            #6
            Tools for detecting alternative splicing events

            In addition to MISO and Cufflinks, ALEXA-seq is another tool that focuses on analysis at the feature level (exon, exon-exon junction, intron, etc.). The manuscript describes the approach. A project level summary of the output can be found here for a series of RNA-seq libraries corresponding to normal breast tissues FAC sorted into various subtypes. Here is a specific example of a gene reported by ALEXA-seq as alternatively expressed: CA12. Another simpler example from a comparison of 5-FU sensitive and resistant cells: UMPS.

            Comment

            • xguo
              Member
              • Jul 2008
              • 48

              #7
              Does Alex-Seq allow statistical comparison of two groups of samples for alternative splicing, especially paired analysis for multiple normal-tumor paired samples? As far as I know, Cuffdiff doesn't have the capability to do paired comparison right now.

              thanks

              Comment

              • malachig
                Senior Member
                • Aug 2010
                • 117

                #8
                Yes, you can define arbitrary numbers of pairwise and groupwise comparisons in any combination.

                e.g.

                Tumor #1 vs. Normal #1 (pairwise)
                All Tumors vs. All Normals (groupwise)
                Myc Amplified Tumors vs. Non-Amplified (groupwise)

                Comment

                • xguo
                  Member
                  • Jul 2008
                  • 48

                  #9
                  thanks, malachig,

                  I'm trying to use Alexa-Seq for the splicing analysis. The comprehensive comprison of different features is very useful for the identification of splicing events. I understand exonJunction and exonBoundary annotation files with different length should be downloaded for sequence libraries with different read length. I'm wondering if I can use Alexa-Seq to analyze sequence data with different read length together.

                  The second question is about the pre-processing of raw reads. I have fastq file for each library. Can I omit the pre-processing and start the pipeline with the mapping of fastq files to repeats, exons, introns, etc?

                  thanks
                  Xiang

                  Comment

                  • shobbir
                    Junior Member
                    • Mar 2012
                    • 7

                    #10
                    i got back my first dataset from an 75bp paired end mRNAseq run. we have run a cuffdiff, but our bioinformatician, bless his cotton socks, is a complete novice, and I know next to nothing about cuffdiff. i have some simple questions:

                    we are interested in differences in global splicing. we are comparing normal vs patient samples and the affected patient has a splice site mutation in the causative gene. however although there is a very significant difference for the causative gene in the isoform_exp.diff table (we know that in the patient exon 6 is skipped and in the isoform_exp.diff table we observe that the isoform which includes exon 6 is massively downregulated in the patient data), the gene does not show up in the spicing.diff table. but it should do since we know that the patients have this splice site mutation. why is this?

                    is the isoform_exp.diff table itself useful for information regarding differences in alternative splicing? or should i only rely on the splicing.diff table?

                    thanks so much

                    Comment

                    • Simon Anders
                      Senior Member
                      • Feb 2010
                      • 995

                      #11
                      You could also try out tool, DEXSeq. See our paper (doi:10.1101/gr.133744.111) for a discussion of its advantages compared to the other tools mentioned in this tread.

                      Comment

                      • shobbir
                        Junior Member
                        • Mar 2012
                        • 7

                        #12
                        looks interesting, thanks. will definitely give it a go. we are currently running MISO - what do you think of this one?

                        Comment

                        • areyes
                          Senior Member
                          • Aug 2010
                          • 165

                          #13
                          MISO does not take into account biological variation. The disadvantages of this are explained in the paper that Simon mentioned.

                          Comment

                          • shobbir
                            Junior Member
                            • Mar 2012
                            • 7

                            #14
                            Ok thanks guys, we have run the DEXseq and the results look more promising. I have a question regarding statistics:

                            We ran 2 experiments, the first was mum vs affected female (4 replicates each) and the second was scrambled siRNA vs knockdown (4 replicates each) - the affected female has a mutation in the same gene we knocked down. In the mum vs affected female the DEXseq detected 2951 genes with differential exon usage with FDR 0.1. However, in the scrambled vs knockdown it only detected 81 genes with FDR 0.1 (39 of these were also present in the mum vs affected female list).

                            I was wondering could we be less stringent for our cut-off for the knockdown data - when we filter using p-value<0.01 for example we get 1057 genes with 360 of them also found to be present in the patient data.

                            I know next to nothing about stats, but are p-values completely worthless in this type of analysis? Are they ok to use when we have four replicates each for each condition. Or do p-values not take into account the consistency/variation of counts across replicates? Is this something that only adjusted p-values do?

                            Comment

                            Latest Articles

                            Collapse

                            • SEQadmin2
                              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                              by SEQadmin2


                              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                              The systematic characterization of the human proteome has
                              ...
                              07-20-2026, 11:48 AM
                            • SEQadmin2
                              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                              by SEQadmin2



                              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                              ...
                              07-09-2026, 11:10 AM
                            • SEQadmin2
                              Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                              by SEQadmin2



                              Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                              There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                              07-08-2026, 05:17 AM

                            ad_right_rmr

                            Collapse

                            News

                            Collapse

                            Topics Statistics Last Post
                            Started by SEQadmin2, Today, 11:41 AM
                            0 responses
                            9 views
                            0 reactions
                            Last Post SEQadmin2  
                            Started by SEQadmin2, 07-20-2026, 11:10 AM
                            0 responses
                            23 views
                            0 reactions
                            Last Post SEQadmin2  
                            Started by SEQadmin2, 07-13-2026, 10:26 AM
                            0 responses
                            35 views
                            0 reactions
                            Last Post SEQadmin2  
                            Started by SEQadmin2, 07-09-2026, 10:04 AM
                            0 responses
                            45 views
                            0 reactions
                            Last Post SEQadmin2  
                            Working...